<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03040180</url>
  </required_header>
  <id_info>
    <org_study_id>REG-32-2016</org_study_id>
    <nct_id>NCT03040180</nct_id>
  </id_info>
  <brief_title>Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer</brief_title>
  <acronym>nECT</acronym>
  <official_title>Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized Clinical Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of neoadjuvant&#xD;
      electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative&#xD;
      clinical setting, using an endoscopic electroporation device (EndoVE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electroporation of cancer cells allows for a greater concentration of chemotherapy drugs to&#xD;
      enter the tumor cells. The uptake of the chemotherapeutic drug is aided through the&#xD;
      application of short electric pulses to the tumor mass (referred to as - Electrochemotherapy&#xD;
      or ECT). The pulses make the tumor cells more porous which allows the drug easier access into&#xD;
      the cancer cells, whereas other tissues and organs in the body remain relatively poor at&#xD;
      absorbing the drug, thereby reducing the potential side effects on healthy tissues.&#xD;
      Procedures with electrochemotherapy have previously been applied to human patients in other&#xD;
      countries of the EU, the US and Japan.&#xD;
&#xD;
      The drug concentration used is significantly reduced due to the more targeted absorption by&#xD;
      the tumor and this significantly reduces side effects normally associated with chemotherapy.&#xD;
&#xD;
      A large number of preclinical and clinical Phase I and I/II studies have demonstrated the&#xD;
      efficiency and safety of ECT. These studies have included patients with melanoma, head and&#xD;
      neck squamous cell carcinoma, merkel cell carcinomas, basal cell carcinoma and adenocarcinoma&#xD;
      nodules.&#xD;
&#xD;
      An endoscopic system (EndoVE ) for delivering the electric pulses to gastrointestinal tumors&#xD;
      has recently been developed. The treatment procedure is similar to standard endoscopic&#xD;
      colorectal examination (therapeutic colonoscopy) with the added element of an intravenous&#xD;
      injection of bleomycin followed by the delivery of electric pulses (each one less than 1msec&#xD;
      in duration). The pulses are endoscopically delivered directly to the tumor mass. The entire&#xD;
      procedure is minimally invasive and completely ambulatory. A successful treatment will cause&#xD;
      the tumor to shrink in size in the weeks following the procedure.&#xD;
&#xD;
      The objective of this study is to investigate the efficacy and safety of this approach in&#xD;
      downsizing locally advanced rectal tumors prior to intended curative surgery.&#xD;
&#xD;
      Time frame:&#xD;
&#xD;
        1. All patients will be treated with standard neoadjuvant chemoradiation therapy prior to&#xD;
           enrollment in this trial.&#xD;
&#xD;
        2. Alle patients will have PET/MRI scans performed twice to evaluate treatment response&#xD;
           (before and after ECT)&#xD;
&#xD;
        3. ECT treatment will be performed 4 weeks prior to surgery outlined by MDT.&#xD;
&#xD;
        4. Alle patients will be followed up for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathologic tumor regression following electrochemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with histopathologic tumor regression following elctrochemotherapy as assesed by histopathological evaluation of Tumor Regression Grade (Mandard Classification, TRG 1-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment safety of electrochemotherapy</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assesed by CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety of surgery following electrochemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with compromized surgery following electrochemotherapy assesed by R1 resection rate, CRM involvement, non-mesorectal resection plane, and post operative complications according to Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression according to Hybrid PET/MRI following electrochemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Tumor regression as assesed by tumor stage (T-stage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Immunologic response following electrochemotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Tumor immunologic infiltration as assesed by the Immunoscore through immunohistochemical analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <condition>Electrochemotherapy</condition>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Down Staging</condition>
  <arm_group>
    <arm_group_label>Electrochemotherapy with bleomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.&#xD;
BSA by Du Bois formula.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Electrochemotherapy with bleomycin</intervention_name>
    <description>Systemic injection, once only treatment</description>
    <arm_group_label>Electrochemotherapy with bleomycin</arm_group_label>
    <other_name>ATC code L01DC01</other_name>
    <other_name>EV substance code SUB00844MIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoVE</intervention_name>
    <description>Electroporation using an endoscopic electroporation device</description>
    <arm_group_label>Electrochemotherapy with bleomycin</arm_group_label>
    <other_name>Endoscopic electroporation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be mentally capable of understanding the information given.&#xD;
&#xD;
          2. Patients must give written informed consent.&#xD;
&#xD;
          3. Men or women aged at least 18 years.&#xD;
&#xD;
          4. Histologically verified rectal tumor (adenocarcinoma)&#xD;
&#xD;
          5. Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with&#xD;
             neoadjuvant therapy followed by surgical excision (UICC stadium II-III).&#xD;
&#xD;
          6. ASA class I-III (Classification of the American Society of Anesthesiology)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coagulation disorders&#xD;
&#xD;
          2. Highly inflamed gastrointestinal tissue which is ulcerated and bleeding&#xD;
&#xD;
          3. Patients with ICD or pacemaker units.&#xD;
&#xD;
          4. Patients with epilepsy.&#xD;
&#xD;
          5. Pregnancy or lactation/breastfeeding.&#xD;
&#xD;
          6. Patients with known Hepatitis B/C or HIV infection.&#xD;
&#xD;
          7. Patients who have undergone treatment with bevacizumab within 4 weeks prior to&#xD;
             enrolment in this trial.&#xD;
&#xD;
          8. Patients with concomitant use of phenytoin.&#xD;
&#xD;
          9. Patients with concomitant use of clozapine.&#xD;
&#xD;
         10. Concurrent treatment with an investigational medicinal product.&#xD;
&#xD;
         11. Patients with any other clinical condition or prior therapy that, in the opinion of&#xD;
             the investigator, would make the patient unsuitable for the study or unable to comply&#xD;
             with the study recruitments.&#xD;
&#xD;
         12. Patients with contraindications for PET/MRI scan:&#xD;
&#xD;
         13. Advanced tumor stage, UICC stage IV.&#xD;
&#xD;
         14. Acute pulmonary infection.&#xD;
&#xD;
         15. Medical history of severe pulmonary disease.&#xD;
&#xD;
         16. Previous allergic reactions to bleomycin.&#xD;
&#xD;
         17. Previous cumulative dose of bleomycin exceeding 250.000 IU/m2.&#xD;
&#xD;
         18. Pre-existing renal dysfunction. Creatinine clearance &lt; 40 ml/min.&#xD;
&#xD;
         19. Platelet count ≤50 mia/l.&#xD;
&#xD;
         20. Prothrombin time ≥ 40 sec&#xD;
&#xD;
         21. Patients registered in the Danish Tissue Register (Vaevsanvendelsesregistret)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismail Gögenur, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, Zealand University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie Gehl, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of oncology, herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ismail Gögenur, MD, DMSc</last_name>
    <phone>+45 26336426</phone>
    <email>igo@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rasmus P Vogelsang, MD</last_name>
    <phone>+45 27351103</phone>
    <email>rvo@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Herlev</city>
        <state>Capitol Region</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Gehl, MD, DMSc</last_name>
      <phone>+45 38683868</phone>
      <email>karen.julie.gehl@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Surgery</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismail Gögenur, MD, DMSc</last_name>
      <phone>+45 26336426</phone>
      <email>igo@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>Rasmus P Vogelsang, MD</last_name>
      <phone>+45 27351103</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms, primary</keyword>
  <keyword>Cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>rectal cancer, locally advanced</keyword>
  <keyword>Electrochemotherapy</keyword>
  <keyword>Electroporation</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>Antineoplastic, antibodies</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Pathologic processes</keyword>
  <keyword>Neoplastic processes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

